Reagents and methods for detecting PNH type II white blood cells and their identification as risk factors for thrombotic disorders
AssigneeAlexion Pharmaceuticals, Inc.
InventorsMayur Movalia, Andrea Illingworth, Susan Faas McKnight, Russell P. Rother
Life of this patent
Estimating the term…
Abstract
The disclosure relates to methods for detecting PNH Type II cell populations in biological samples as well as methods for determining whether a patient is at an increased risk for developing thrombocytopenia or thrombosis based on the percentage of PNH Type II cells in the patient's blood. The disclosure also features reagents and conjugates for use in the methods.
Claims19
A method for treating a patient, the method comprising administering to a patient in need thereof one or both of an anti-thrombotic therapy and an anti-thrombocytopenic therapy, wherein the patient has been determined to have a paroxysmal nocturnal hemoglobinuria (PNH) Type II white blood cell population that is between 1.2% and 65.3%, inclusive of 1.2% and 65.3%, of the patient's total granulocytes.
A method for treating a patient, the method comprising administering to a patient in need thereof eculizumab and one or both of an anti-thrombotic therapy and an anti-thrombocytopenic therapy, wherein the patient has been determined to have a paroxysmal nocturnal hemoglobinuria (PNH) Type II white blood cell population that is between 1.2% and 65.3%, inclusive of 1.2% and 65.3%, of the patient's total granulocytes.
Dependencies are inferred from the claim text.